Abstract |
A fluorine-containing anthracycline, ME2303, given intravenously once a week for 4 weeks at the maximum tolerated doses showed better therapeutic effects against 2 gastric, 3 lung and 2 human breast tumor xenografts than did adriamycin (ADM) at the maximum tolerated dose. Among the tumors, ME2303 showed a better effect against St-40, a well-differentiated human gastric adenocarcinoma, against which ADM showed only a marginal effect. Likewise, ME2303 was more effective against Lu-24 human small cell carcinoma and MX-1 human medullary tubular adenocarcinoma than ADM. Notably, the Lu-24 tumor, developed in nude mice, disappeared after the treatment in 3 out of 6 mice. ME2303 would be an interesting compound for phase I and II clinical studies in the future.
|
Authors | T Tsuruo, S Sato, K Yusa |
Journal | Japanese journal of cancer research : Gann
(Jpn J Cancer Res)
Vol. 80
Issue 7
Pg. 686-9
(Jul 1989)
ISSN: 0910-5050 [Print] Japan |
PMID | 2507492
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Doxorubicin
(analogs & derivatives, therapeutic use)
- Drug Tolerance
- Humans
- Mice
- Mice, Nude
- Neoplasm Transplantation
- Neoplasms, Experimental
(drug therapy)
- Structure-Activity Relationship
|